A significant risk for cognitive impairment was observed in adults with short sleep duration and cardiometabolic risk factors, such as hypertension or diabetes.
News
Advertisement
Neurology News Network for the week ending June 8, 2019.
Advertisement
Advertisement
Advertisement
The FDA has approved an sBLA for deflazacort that expands the label to patients aged 2 to 5 with Duchenne muscular dystrophy.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Efgartigimod Treatment for CIDP Leads to Increased Spending, Study Shows
2
Newly Unveiled EPIC Trial Pins Myasthenia Gravis Medications Nipocalimab Against Efgartigimod for Efficacy
3
Phase 3 MG0020 Trial Highlights Success of Self-Administered Rozanolixizumab for Generalized Myasthenia Gravis
4
B-Cell Modulator Obexelimab Shows Pronounced Relapse Reduction in Phase 2 MoonStone Trial
5
